Skip to main content
Premium Trial:

Request an Annual Quote

Opposition Proceedings to Benitec UK Patent Ended

Premium

Benitec Biopharma announced this week that a challenge to a key UK patent has been withdrawn, and that the amended claims in the patent have been accepted by the United Kingdom Intellectual Property Office.

According to the company, the patent — GB 2353282 — had been challenged in 2010 by a UK-based law firm on behalf of an unknown client. Benitec said it responded to all the issues raised in the challenge, deciding to “slightly amend” the IP to “provide greater clarity, in particular that the claims were to double-stranded constructs.”

The patent claims the use of recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue, organ, or whole organism, according to its abstract.

Objections raised to certain of the amended claims were later dropped, Benitec said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.